Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;7(3):409-17.
doi: 10.1161/CIRCHEARTFAILURE.113.000952. Epub 2014 Mar 25.

Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis

Bryan Kestenbaum  1 , Michael C Sachs  2 , Andy N Hoofnagle  2 , David S Siscovick  2 , Joachim H Ix  2 , Cassianne Robinson-Cohen  2 , Joao A C Lima  2 , Joseph F Polak  2 , Marc Blondon  2 , John Ruzinski  2 , Denise Rock  2 , Ian H de Boer  2
Affiliations

Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis

Bryan Kestenbaum et al. Circ Heart Fail. 2014 May.

Abstract

Background: Fibroblast growth factor-23 (FGF-23) is a phosphate regulatory hormone that directly stimulates left ventricular hypertrophy in experimental models. The role of FGF-23 in cardiovascular disease development in the general population is unclear. We tested associations of FGF-23 with major subclinical and clinical cardiovascular disease outcomes in a large prospective cohort.

Methods and results: We evaluated 6547 participants from the Multi-Ethnic Study of Atherosclerosis (MESA) who were initially free of cardiovascular disease. We measured serum FGF-23 using the Kainos immunoassay. The MESA measured left ventricular mass by MRI, coronary calcium by computed tomography, and carotid intima-media thickness by ultrasound. The MESA adjudicated incident heart failure, coronary heart disease, and stroke by medical record review. After adjustment, the highest FGF-23 quartile was associated with an estimated 2.4-g greater left ventricular mass (95% confidence interval, 0.4-4.5 greater) and a 26% greater odds of higher coronary calcium scores (95% confidence interval, 9%-46% greater) compared with the lowest quartile. During 7.5-year follow-up, each 20-pg/mL higher FGF-23 concentration was associated with a 19% greater risk of heart failure (95% confidence interval, 3%-37% greater) and a 14% greater risk of coronary heart disease (95% confidence interval, 1%-28% greater). FGF-23 was not associated with carotid intima-media thickness or stroke.

Conclusions: Higher serum FGF-23 concentrations are associated with subclinical cardiac disease and with new heart failure and coronary disease events, but not with carotid intima-media thickness or stroke. FGF-23 may be a novel cardiovascular risk factor in the general population.

Keywords: cardiovascular diseases; carotid intima-media thickness; coronary disease; fibroblast growth factor 23; heart failure; hypertrophy, left ventricular; stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cumulative incidences of cardiovascular events by serum FGF-23 concentration
Y-axis depicts the unadjusted cumulative incidences of heart failure, coronary heart disease, and stroke, respectively; X-axis depicts follow-up time in the study with interval censoring. Data are presented by quartiles of serum FGF-23 concentration with the number at risk and cumulative number of events by year described below the X-axis.
Figure 2
Figure 2. Associations of serum FGF-23 concentration with incident heart failure and coronary heart disease events by subgroup
Forest plot depicting associations of 20-pg/mL greater serum FGF-23 concentrations with incident heart failure and incident coronary heart disease events by subgroup. The X-axis represents the relative risk (closed circles) and 95% confidence interval (horizontal lines) for each association. The vertical hashed lines represent hazards ratio for the full cohort and the light grey vertical lines represent a hazard ratio of 1.0.
See this image and copyright information in PMC

References

    1. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of fgf23 demonstrates an essential physiological role of fgf23 in phosphate and vitamin d metabolism. J Clin Invest. 2004;113:561–568. - PMC - PubMed
    1. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC. Fgf-23 inhibits renal tubular phosphate transport and is a phex substrate. Biochem Biophys Res Commun. 2001;284:977–981. - PubMed
    1. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ. The autosomal dominant hypophosphatemic rickets (adhr) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86:497–500. - PubMed
    1. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215. - PubMed
    1. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M. Fgf23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408. - PMC - PubMed

Publication types

MeSH terms